# Noga Yerushalmi

> Noga Yerushalmi is a Series A investor at M Ventures backing Health Care and Medical. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [M Ventures](https://shizune.co/investors/profile/merckventures)
- Total investments: 2
- Last investment: Jul 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/noga-yerushalmi-5699389/

Noga Yerushalmi is a Series A investor at M Ventures focused on Health Care and Medical. Noga joined the team in January 2017 and is the Head of the Bioincubator in Insrael. Noga is a graduate of Tel-Aviv University, and did her postdoctoral fellowship at NIH, USA. She has over 15 years of experience in the Israeli Biotech industry, leading R&D projects in different research fields and business development opportunities.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Medical | 1 | 50% |
| Life Science | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Venture - Series Unknown | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 1 | 50% |
| Norway | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Actithera | Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M | Series A | Jul 09, 2025 |  |
| Nucleai | Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects. | $14M | Venture - Series Unknown | Apr 03, 2024 |  |

2 of 2 investments shown.

## Co-investors
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 1 deal together
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 1 deal together
- [Bioqube Ventures](https://shizune.co/investors/profile/bioqube-ventures) — VC Fund, 1 deal together
- [Grove Ventures](https://shizune.co/investors/profile/grove-ventures) — VC Fund, 1 deal together
- [Hadean Ventures](https://shizune.co/investors/profile/hadean-ventures) — VC Fund, 1 deal together
- [Innovestor](https://shizune.co/investors/profile/innovestor) — VC Fund, 1 deal together

## About M Ventures

VC Fund · Amsterdam, The Netherlands

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

5 contacts available at M Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Christian Patze | Associate, Performance Materials | https://shizune.co/investors/profile/christian-patze |
| Noga Yerushalmi | Head of Israel Bio-incubator | https://shizune.co/investors/profile/noga-yerushalmi |
| Sarah Luppino | Associate | https://shizune.co/investors/profile/sarah-luppino |
| Alexander Hoffmann | Principal | https://shizune.co/investors/profile/alexander-hoffmann |
| Alicia Iruzun Lafitte | Principal | https://shizune.co/investors/profile/alicia-iruzun-lafitte |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Noga Yerushalmi invest in?

Noga Yerushalmi invests primarily in Health Care, Medical and Life Science startups, most often at Series A and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Noga Yerushalmi last invest?

The most recent investment recorded for Noga Yerushalmi closed in Jul 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co